Drug Trial Radar · NCT01277341
Safety and Efficacy of Bepotastine Besilate Nasal Spray in the Treatment of Seasonal Allergic Rhinitis
Last checked: Nov 20, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
601
Actual
Start
Dec 2010
Primary completion
Feb 2011
Study completion May 2011
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Jan 14, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an efficacy study of bepotastine besilate nasal spray in seasonal allergic rhinitis.
Conditions
- Seasonal Allergic Rhinitis
Interventions
Bepotastine Besilate Nasal Spray 2% Twice a dayDrug
nasal spray
Bepotastine Besilate Nasal Spray 3% Twice a dayDrug
nasal spray
Bepotastine Besilate Nasal Spray 4% Twice a dayDrug
nasal spray
Placebo Nasal SprayDrug
nasal spray
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Baseline (Pre-Dose) in Subject-rated Reflective TNSSTime frame: Baseline, 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ISTA Pharmaceuticals, Inc.
Irvine, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.